Search Result

Results for "

α-amylase activity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylases (39) Amyloid-β (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (3) Bacterial (1) Bcl-2 Family (1) Biochemical Assay Reagents (2) Caspase (1) Cholinesterase (ChE) (1) COX (3) Dipeptidyl Peptidase (3) DNA/RNA Synthesis (1) Drug Metabolite (1) Endogenous Metabolite (1) Fatty Acid Synthase (FASN) (2) Fungal (2) GLUT (1) Glycosidase (29) HDAC (1) Lipase (2) MDM-2/p53 (1) Monoamine Oxidase (1) NF-κB (5) NO Synthase (1) NOD-like Receptor (NLR) (2) P2Y Receptor (1) p38 MAPK (1) Parasite (1) PARP (1) Phosphatase (1) PPAR (1) Pregnane X Receptor (PXR) (1) Pyroptosis (2) Reactive Oxygen Species (ROS) (2) Reference Standards (3) SARS-CoV (1) SOD (1) TNF Receptor (1) Tyrosinase (1) β-glucuronidase (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (2) Endocrinology (3) Infection (3) Inflammation/Immunology (17) Metabolic Disease (44) Neurological Disease (3)

By Targets:

Amylases (39)

Amyloid-β (1)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (3)

Bacterial (1)

Bcl-2 Family (1)

Biochemical Assay Reagents (2)

Caspase (1)

Cholinesterase (ChE) (1)

COX (3)

Dipeptidyl Peptidase (3)

DNA/RNA Synthesis (1)

Drug Metabolite (1)

Endogenous Metabolite (1)

Fatty Acid Synthase (FASN) (2)

Fungal (2)

GLUT (1)

Glycosidase (29)

HDAC (1)

Lipase (2)

MDM-2/p53 (1)

Monoamine Oxidase (1)

NF-κB (5)

NO Synthase (1)

NOD-like Receptor (NLR) (2)

P2Y Receptor (1)

p38 MAPK (1)

Parasite (1)

PARP (1)

Phosphatase (1)

PPAR (1)

Pregnane X Receptor (PXR) (1)

Pyroptosis (2)

Reactive Oxygen Species (ROS) (2)

Reference Standards (3)

SARS-CoV (1)

SOD (1)

TNF Receptor (1)

Tyrosinase (1)

β-glucuronidase (1)

By Research Areas:

Cancer (10)

Cardiovascular Disease (2)

Endocrinology (3)

Infection (3)

Inflammation/Immunology (17)

Metabolic Disease (44)

Neurological Disease (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132179

Fucoidan Maximum Cited Publications 6 Publications Verification	Glycosidase	Cardiovascular Disease Metabolic Disease Cancer
Fucoidan, a biologically active polysaccharide, is an efficient inhibitor of α-amylase and α-glucosidase. Anticoagulant, antitumor, antioxidant and antisteatotic activities .

HY-113159

Docosapentaenoic acid (22n-3) Clupanodonic acid	Amylases Glycosidase	Metabolic Disease Inflammation/Immunology
Docosapentaenoic acid (22n-3) is a component of phospholipids. Docosapentaenoic acid 22n-3 has inhibitory activity against *α-amylase* and α-glucosidase, with IC₅₀s value of 17 μg/mL and 22 μg/mL, respectively. Docosapentaenoic acid 22n-3 increases cell vitality. Docosapentaenoic acid 22n-3 has a weak anti-inflammatory effect .

HY-N1425

Tiliroside 3 Publications Verification	Others	Metabolic Disease
Tiliroside, a glycosidic flavonoid, possesses anti-diabetic activities. Tiliroside is a noncompetitive inhibitor of *α-amylase* with a K_i value of 84.2 μM. Tiliroside inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract .

HY-153102

G3-CNP	Biochemical Assay Reagents	Others
G3-CNP is an α-amylase substrate. The absorbance of G3-CNP cleavage product 2-chloro-4-nitrophenol is measured at 405 nm, which can be used to detect enzyme activity .

HY-126052

Gnetol	COX Tyrosinase HDAC	Metabolic Disease Cancer
Gnetol is a phenolic compound isolated from the root of Gnetum montanum . Gnetol potently inhibits COX-1 (IC₅₀ of 0.78 μM) and HDAC. Gnetol is a potent tyrosinase inhibitor with an IC₅₀ of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis. Gnetol has antioxidant, antiproliferative, anticancer and hepatoprotective activity. Gnetol also possesses concentration-dependent α-Amylase, α-glucosidase, and adipogenesis activities .

HY-N2376

Chrysin-7-O-glucuronide 1 Publications Verification	Glycosidase Amylases NF-κB	Metabolic Disease Inflammation/Immunology
Chrysin-7-O-glucuronide is a flavonoid found in Scutellaria baicalensis. Chrysin-7-O-glucuronide inhibits α-glucosidase and *α-amylase* with IC₅₀ values of 612.13 and 980.73 μg/mL. Chrysin-7-O-glucuronide suppresses NF-κB signaling activity. Chrysin-7-O-glucuronide scavenges free radicals, acts as a tight junction protector, and mitigates intestinal mucosal barrier injury. Chrysin-7-O-glucuronide can be used for the research of type 2 diabetes and severe acute pancreatitis-induced intestinal mucosal barrier injury .

HY-112835

Ethylidene-4-nitrophenyl-a-D-Maltoheptaoside pNP-G7	Amylases Glycosidase	Inflammation/Immunology
Ethylidene-4-nitrophenyl-α-D-Maltoheptaoside (EPS; pNP-G7) serves as a substrate for α-amylase. In the presence of an auxiliary enzyme such as α-glucosidase (α-glucosidase), Ethylidene-4-nitrophenyl-α-D-Maltoheptaoside is degraded by amylase (Amylase) to release a chromophore, enabling the measurement of amylase activity. Ethylidene-4-nitrophenyl-α-D-Maltoheptaoside is applicable for the diagnosis of pancreatitis ^[2].

HY-160113

Sodium phosphate buffer 0.02 M, pH 6.9	Biochemical Assay Reagents	Others
Sodium phosphate buffer 0.02 M, pH 6.9 is a commonly used aqueous biological buffer that maintains a stable pH value. Sodium phosphate buffer 0.02 M, pH 6.9 is often used in enzyme activity assays, such as α-amylase assays. Sodium phosphate buffer 0.02 M, pH 6.9 is prepared by mixing disodium hydrogen phosphate (Na₂HPO₄) (HY-B2243) and sodium dihydrogen phosphate (NaH₂PO₄) (HY-Y0308) to a total concentration of 0.02 M .

HY-Y0598

trans-Chalcone 2 Publications Verification Benzylideneacetophenone	Fatty Acid Synthase (FASN) Apoptosis Fungal	Inflammation/Immunology Cancer
trans-Chalcone, isolated from Aronia melanocarpa skin, is a biphenolic core structure of flavonoids precursor. trans-Chalcone is a potent fatty acid synthase (FAS) and *α-amylase* inhibitor. trans-Chalcone causes cellcycle arrest and induces apoptosis in the breastcancer cell line MCF-7. trans-Chalcone has antifungal and anticancer activity .

HY-N8599

Cichoriin 2 Publications Verification	Amylases Glycosidase Lipase Dipeptidyl Peptidase p38 MAPK PPAR P2Y Receptor NOD-like Receptor (NLR) SARS-CoV Pyroptosis GLUT Angiotensin-converting Enzyme (ACE) NF-κB	Infection Metabolic Disease Inflammation/Immunology
Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against *α-amylase, α-glucosidase, pancreatic lipase* and DPP-IV, with IC₅₀ values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting P2Y₁₄R (IC₅₀ = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2 .

HY-W068682

1-Hydroxyphenazine Hemipyocyanine; 1-Phenazinol; Hemi-pyocyanin	Amylases Bacterial	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
1-Hydroxyphenazine (Hemipyocyanine; 1-Phenazinol; Hemi-pyocyanin) is an inhibitor for *α-Amylase* with an IC₅₀ of 3.1 μg/mL . 1-Hydroxyphenazine exhibits anticancer and anti-inflammatory activity against cells A549, 1321N1 and RAW264.7, antifungal and antibacterial activity against strains Candida albicans, Aspergillus fumigatus, Escherichia coli and Xanthomonas campestris .

HY-N4309

Lotusine	Amylases Glycosidase	Neurological Disease Metabolic Disease Cancer
Lotusine is an orally active signaling pathway modulator and enzyme inhibitor, with an IC₅₀ of 30.60 μg/mL against *α-amylase* and an IC₅₀ of 36.15 μg/mL against α-glucosidase. Lotusine inhibits the EGFR-Akt-ERK signaling pathway by reducing the levels of phosphorylated EGFR, Akt and ERK. Lotusine induces apoptosis, triggers G₀/G₁ cell cycle arrest and inhibits cancer cell proliferation. Lotusine reduces lipid peroxidation and increases the activities of SOD, CAT and GPx. Lotusine is applicable to researches related to non-small cell lung cancer, type 2 diabetes and autism spectrum disorder .

HY-200541

Dihydro-α-ionone	Others	Metabolic Disease
Dihydro-α-ionone is a volatile compound found in the essential oil of Persicaria hydropiper L. leaves. The essential oil can inhibit α-glucosidase and α-amylase activities .

HY-N1731

2′-Hydroxy-5′-methoxyacetophenone	NF-κB COX TNF Receptor NO Synthase Reactive Oxygen Species (ROS) Parasite	Infection Metabolic Disease Inflammation/Immunology Cancer
2'-Hydroxy-5'-methoxyacetophenone is an acetophenone derivative with acaricidal activities. 2'-Hydroxy-5'-methoxyacetophenone attenuates the inﬂammatory response via NF-κB signaling pathway. 2'-Hydroxy-5'-methoxyacetophenone exhibits significant inhibitory activity against α-amylase, collagenase and aldose reductase (AR) with IC₅₀s of 0.928, 3.264 and 20.046 μM, highlighting its potential in combating diabetes. 2'-Hydroxy-5'-methoxyacetophenone exhibits anti-ovarian cancer activity .

HY-N12999

Stigmast-5-en-3-ol	Apoptosis Bcl-2 Family Caspase MDM-2/p53 PARP Amylases	Metabolic Disease Endocrinology Cancer
Stigmast-5-en-3-ol induces cancer cell apoptosis and inhibits proliferation by increasing the production of Bax, Caspase-9, p53, and PARP cleavage and reducing Bcl-xl expression. Stigmast-5-en-3-ol exhibits potent inhibitory activity against glucoamylase and *α-amylase* and possesses high antioxidant activity. Stigmast-5-en-3-ol can be used in the research of diseases such as leukemia, breast cancer, type 2 diabetes, and obesity .

HY-N10413

Diphlorethohydroxycarmalol	Glycosidase	Metabolic Disease
Diphlorethohydroxycarmalol, a kind of phlorotannin, is an orally active α-glucosidase and *α-amylase* inhibitor with IC₅₀s of 0.16 mM and 0.53 mM, respectively. Diphlorethohydroxycarmalol has anti-diabetic activities .

HY-N9454

Garcinoic acid	Pregnane X Receptor (PXR) COX NF-κB Amylases β-glucuronidase DNA/RNA Synthesis Amyloid-β NOD-like Receptor (NLR) Pyroptosis	Cancer
Garcinoic acid is an orally active anti-inflammatory agent that crosses the blood-brain barrier. Garcinoic acid also enhances efferocytosis and enzyme/receptor regulation, and selectively inhibits human COX-2, porcine *α-amylase, Saccharomyces cerevisiae α-glucosidase* and human DNA polymerase β (IC₅₀=11 μM), as well as activates human PXR. Garcinoic acid enhances macrophage efferocytosis via receptors such as MerTK and LRP-1, and promotes the production of pro-resolving lipid mediators. Garcinoic acid inhibits NF-κB activation and pro-inflammatory cytokine secretion, interferes with Aβ aggregation, downregulates NLRP3 inflammasome activity, and binds to targets including CD44 and EGFR to inhibit leukemia cell proliferation. The pharmacological activities of Garcinoic acid, such as antioxidant, anti-inflammatory and lipid metabolism-regulating effects, are widely used in studies related to various diseases including atherosclerosis, Alzheimer's disease, type 2 diabetes, inflammatory bowel disease and viral pneumonia .

HY-149008

α-Amylase-IN-3	Amylases Cholinesterase (ChE)	Inflammation/Immunology
α-Amylase-IN-3 (Compound 4) is the inhibitor for *α-Amylase, AChE* and AChE with IC₅₀s of 18.04 μM, 21.04 μM and 22.2 μM, respectively. α-Amylase-IN-3 exhibits antioxidant activity. α-Amylase-IN-3 can be used in research of diabetes and oxidative stress associated disease .

HY-155241

α-Amylase/α-Glucosidase-IN-4	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-4 (compound 5) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC₅₀s of 0.15 μM and 1.10 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .

HY-175605

α-Amylase/α-Glucosidase-IN-21	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-21 (Compound 4) is a dual-functional inhibitor of α-Glucosidase and *α-Amylase* with IC₅₀s of 0.27 and 0.19 µg/mL for α-Glucosidase and α-Amylase, respectively. α-Amylase/α-Glucosidase-IN-21 has an antidiabetic activity.α-Amylase/α-Glucosidase-IN-21 can be used for diabetes mellitus research .

HY-W112651

2,4,6-Triphenylaniline	Glycosidase Amylases	Metabolic Disease
2,4,6-Triphenylaniline has anti-diabetic activity and can be encapsulated in nano-emulsions (NE) to enhance stability and permeability. The NE loaded with 2,4,6-Triphenylaniline inhibits α-glucosidase and *α-amylase* .

HY-169737

Inulobiose	Glycosidase Amylases	Metabolic Disease
Inulobiose is a difructan disaccharide that can be isolated from Pistacia vera L.. Inulobiose inhibits α-glycosidase and *α-amylase* activities with IC₅₀s of 1.87 and 40.72 mg/mL, respectively. Inulobiose can be used for the research of diabetes and glomerular filtration rate testing .

HY-149313

α‑Amylase-IN-1	Amylases	Metabolic Disease
α Amylase-IN-1 (Compound 11) is an *α-Amylase* inhibitor with an IC₅₀ value of 0.5509 μM. α Amylase-IN-1 has antioxidant activity with an IC₅₀ value of 53.49 μM for scavenging DPPH free radicals. IC₅₀ can be used in the study of diabetes and oxidative stress-related diseases.

HY-149973

α-Amylase-IN-4	Amylases	Metabolic Disease
α-Amylase-IN-4 (Compd 10y) show maximum inhibition of amylase activity with IC₅₀ value 17.83 ± 0.14 μg/mL .

HY-N8134

2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one	Dipeptidyl Peptidase	Metabolic Disease
2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one is a natural product found in the leaves and stem bark of M. glabra. 2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one displays binding affinities with dipeptidyl peptidase-4 (DPP-4) and *α-Amylase. 2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one has potential antidiabetic activities* .

HY-W207699

MAO-B-IN-46	Monoamine Oxidase Amylases	Neurological Disease Metabolic Disease Inflammation/Immunology
MAO-B-IN-46 (Compound 16) is a selective hMAO-B inhibitor (IC₅₀: 26.8 nM), with weak activity against hMAO-A (IC₅₀: 7.2054 μM). MAO-B-IN-46 (Compound 8) also acts as an *α-amylase* inhibitor (IC₅₀: 19.46 μM). MAO-B-IN-46 exhibits certain neuroprotective effects and shows no significant toxicity to human gingival fibroblasts and SH-SY5Y cells. Additionally, MAO-B-IN-46 can scavenge DPPH and ABTS free radicals, with IC₅₀ values of 17.86 μM and 17.71 μM, respectively. MAO-B-IN-46 can be used in the research of neurodegenerative diseases such as Parkinson's disease, diabetes, and diseases related to oxidative stress resistance .

HY-178935

α-Amylase-IN-14	Amylases Reactive Oxygen Species (ROS)	Metabolic Disease Inflammation/Immunology
α-Amylase-IN-14, a derivative of Nicotinic (HY-B0143), is an α-amylase inhibitor and has good interactions with α-amylase protein (-5.55 kcal/mol). α-Amylase-IN-14 is a dual anti-inflammatory and anti-hyperglycemic agent. α-Amylase-IN-14 exhibits good results against DPPH and ABTS radicals. α-Amylase-IN-14 can be used for the study of diabetes .

HY-174319

α-Amylase/α-Glucosidase-IN-20	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-20 (Compound 6b) is a dual inhibitor of *α-Amylase* and α-Glucosidase with IC₅₀s of 414.57 and 924.15 μM for α-Amylase and α-Glucosidase, respectively. α-Amylase/α-Glucosidase-IN-20 shows a potent anti-diabetic activity, promising for diabetes research .

HY-149557

α-Amylase/α-Glucosidase-IN-5	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-5 (compound 4l) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC₅₀s of 5.96 μM and 1.62 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .

HY-156380

α-Amylase/α-Glucosidase-IN-6	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of *α-amylase* and α-glucosidase, with IC₅₀s of 17.0 and 40.1 µM, respectively. α-Amylase/α-Glucosidase-IN-6 exhibits anti-hyperglycemic activities .

HY-168495

α-Amylase-IN-12	Amylases Glycosidase	Metabolic Disease
α-Amylase-IN-12 (Compound 5e) is an *α-amylase* inhibitor (IC₅₀: 0.15 mM) with a mixed inhibition. α-Amylase-IN-12 has an IC₅₀ of 9.40 mM against α-glucosidase. α-Amylase-IN-12 promotes glucose uptake in yeast cells and exhibits significant antiglycation activity at high concentrations. α-Amylase-IN-12 can be used for the research of diabetes .

HY-162169

α-Amylase/α-Glucosidase-IN-8	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-8 (Compound 7p) is a potent dual inhibitor of *α-amylase* and α-glucosidase, with IC₅₀s of 10.19 and 10.33 μM, respectively. α-Amylase/α-Glucosidase-IN-8 has good anti-oxidant activity(IC₅₀ = 14.93 μM). α-Amylase/α-Glucosidase-IN-8 can be used for the research of diabetes .

HY-N12263

3,5,6,7,8,4'-Hexamethoxyflavone	Amylases	Metabolic Disease
3,5,6,7,8,4'-Hexamethoxyflavone is a inhibitor of *α-Amylase* with the inhibitory activity of 28.3% at 500 μM .

HY-172211

α-Amylase/α-Glucosidase-IN-17	Amylases Glycosidase	Metabolic Disease Cancer
α-Amylase/α-Glucosidase-IN-17 (Compound 3) is an inhibitor of *α-amylase* and α-glucosidase, with IC₅₀ values of 14.61 μM and 25.38 μM, respectively. α-Amylase/α-Glucosidase-IN-17 has certain inhibitory activity against A549 cancer cells. α-Amylase/α-Glucosidase-IN-17 has anti-tumor and anti-diabetic effects .

HY-162390

α-Amylase/α-Glucosidase-IN-11	Amylases Glycosidase	Endocrinology
α-Amylase/α-Glucosidase-IN-11 (Compound 5d) is a isoxazolidine-isatin hybrid with significant antidiabetic activity. α-Amylase/α-Glucosidase-IN-11 competitively inhibits *α-amylase* (IC₅₀ = 30.39 μM) and α-glucosidase (IC₅₀ = 65.1 μM), two key digestive enzymes. α-Amylase/α-Glucosidase-IN-11 does not cross the blood-brain barrier .

HY-N11844

Quercetin 3-(6″-caffeoylsophoroside)	Amylases	Metabolic Disease
Quercetin 3-(6″-caffeoylsophoroside) is an orally active *α-amylase* inhibitor, with an IC₅₀ of 73.66 μg/mL. Quercetin 3-(6″-caffeoylsophoroside) presents in thehydro-methanolic extract of Cardamine hirsuta Linn. Quercetin 3-(6″-caffeoylsophoroside) shows the antidiabetic activities by oxidative stress reduction and α-amylase inhibition. Quercetin 3-(6″-caffeoylsophoroside) can be used for diabetes mellitus research .

HY-N10064

Ficusonolide	Others	Metabolic Disease
Ficusonolide has significant antidiabetic activity with a possible mechanism of interaction with dipeptidyl peptidase-IV (DPP-IV), protein tyrosine phosphatase 1B (PTP-1B), α-glucosidase, and α-amylase.

HY-N7729

Sekikaic acid	Amylases Glycosidase	Metabolic Disease
Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .

HY-N1425R

Tiliroside (Standard)	Reference Standards Others	Metabolic Disease
Tiliroside (Standard) is the analytical standard of Tiliroside. This product is intended for research and analytical applications. Tiliroside, a glycosidic flavonoid, possesses anti-diabetic activities. Tiliroside is a noncompetitive inhibitor of *α-amylase* with a K_i value of 84.2 μM. Tiliroside inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract .

HY-N16656

Ladyginoside A	Amylases Glycosidase	Metabolic Disease Inflammation/Immunology
Ladyginoside A is a triterpenoid saponin found in the leaves of Polyscias fruticosa (L.) Harms. Ladyginoside A has inhibitory activities against *α-amylase* and α-glucosidase, and can regulate carbohydrate metabolism. Ladyginoside A also exhibits potential anti-inflammatory and mast cell stabilizing effects. Ladyginoside A can be used for the researches of inflammation and metabolic disease, such as diabetes .

HY-161429

Antidiabetic agent 5	Amylases Glycosidase	Metabolic Disease
Antidiabetic agent 5 (compound S1) is a antidiabetic agent. Antidiabetic agent 5 inhibits the activity of α-glucosidase and *α-amylase* with IC₅₀ values of 3.91，8.89 μM，respectively. Antidiabetic agent 5 decreases sugar levels. Antidiabetic agent 5 has the potential for the research of type-II diabetes .

HY-159491

DPP-4-IN-11	Dipeptidyl Peptidase Glycosidase Amylases	Metabolic Disease
DPP-4-IN-11 (compound 10) is an orally active DPP-4 inhibitor (IC₅₀=2.75 μM) with anti-type 2 diabetes activity. DPP-4-IN-11 exerts its glucose-lowering effect by inhibiting the activities of α-glucosidase (IC₅₀=3.02 μM) and *α-amylase* (IC₅₀=3.3 μM) .

HY-113159A

Docosapentaenoic acid (22n-3) sodium Clupanodonic acid sodium	Amylases Glycosidase	Metabolic Disease Inflammation/Immunology
Docosapentaenoic acid (22n-3) sodium is a component of phospholipids. Docosapentaenoic acid 22n-3 sodium has inhibitory activity against *α-amylase* and α-glucosidase, with IC₅₀s value of 17 μg/mL and 22 μg/mL, respectively. Docosapentaenoic acid 22n-3 sodium increases cell vitality. Docosapentaenoic acid 22n-3 sodium has a weak anti-inflammatory effect .

HY-168074

4″-C18 EGCG	Amylases Glycosidase	Metabolic Disease Inflammation/Immunology
4″-C18 EGCG is a potent inhibitor of *α-amylase* and α-glucosidase with IC₅₀ values of 3.74 and 0.81 μM, respectively. 4″-C18 EGCG inhibits carbohydrate hydrolases, reduces oxidative stress and inflammation, and exhibits antidiabetic activity. 4″-C18 EGCG also downregulates proinflammatory cytokines and is cytotoxic to primary human peripheral blood mononuclear cells (PBMCs), non-cancer cell lines 3T3-L1, and HEK 293 at 50 μM .

HY-N4309A

Lotusine hydroxide	Amylases Glycosidase	Cardiovascular Disease
Lotusine hydroxide is an orally active signaling pathway modulator and enzyme inhibitor, with an IC₅₀ of 30.60 μg/mL against *α-amylase* and an IC₅₀ of 36.15 μg/mL against α-glucosidase. Lotusine hydroxide inhibits the EGFR-Akt-ERK signaling pathway by reducing the levels of phosphorylated EGFR, Akt and ERK. Lotusine hydroxide induces apoptosis, triggers G₀/G₁ cell cycle arrest and inhibits cancer cell proliferation. Lotusine hydroxide reduces lipid peroxidation and increases the activities of SOD, CAT and GPx. Lotusine hydroxide is applicable to researches related to non-small cell lung cancer, type 2 diabetes and autism spectrum disorder .

HY-168185

α-glucosidase/PTP1B-IN-1	Glycosidase Phosphatase Amylases	Metabolic Disease
α-glucosidase/PTP1B-IN-1 (compound 8a) is a potent α-glucosidase and PTP1B inhibitor with an IC₅₀ value of 66.3 μM and 47.0 μM, respectively. α-glucosidase/PTP1B-IN-1 exhibits excellent activities against *α-amylase* with an IC₅₀ of 30.62 μM. α-glucosidase/PTP1B-IN-1 can dock into the active pockets of α-glucosidase and PTP1B. α-glucosidase/PTP1B-IN-1 has potential to reduce the postprandial blood glucose and is used for Type 2 diabetes mellitus .

HY-N2376R

Chrysin-7-O-glucuronide (Standard)	Reference Standards Glycosidase Amylases NF-κB	Metabolic Disease Inflammation/Immunology
Chrysin-7-O-glucuronide (Standard) is the analytical standard of Chrysin-7-O-glucuronide (Hy-N2376). This product is intended for research and analytical applications. Chrysin-7-O-glucuronide is a flavonoid found in Scutellaria baicalensis. Chrysin-7-O-glucuronide inhibits α-glucosidase and *α-amylase* with IC₅₀ values of 612.13 and 980.73 μg/mL. Chrysin-7-O-glucuronide suppresses NF-κB signaling activity. Chrysin-7-O-glucuronide scavenges free radicals, acts as a tight junction protector, and mitigates intestinal mucosal barrier injury. Chrysin-7-O-glucuronide can be used for the research of type 2 diabetes and severe acute pancreatitis-induced intestinal mucosal barrier injury .

HY-N17215

3,4,6-Tri-O-galloyl-D-glucose 3,4,6-Trigalloylglucose	Amylases Glycosidase	Metabolic Disease Inflammation/Immunology
3,4,6-Tri-O-galloyl-D-glucose (3,4,6-Trigalloylglucose) is an *α-amylase* (*porcine α-amylase* IC₅₀ = 334.6 μM; K_i = 307.5 μM) and α-glucosidase (yeast α-glucosidase IC₅₀ = 46.5 μM; K_i** = 39.9 μM) mixed type inhibitor. 3,4,6-Tri-O-galloyl-D-glucose exhibits free radical scavenging ability, ferric-reducing power, and antioxidant activity. 3,4,6-Tri-O-galloyl-D-glucose can be used for the research of diabetes .

HY-P2055

A-57696	Endogenous Metabolite	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

HY-N17674

Luteolin 4'-O-β-D-glucuronopyranoside	Amylases	Metabolic Disease
Luteolin 4'-O-β-D-glucuronopyranoside is a flavonoid glycoside. Luteolin 4'-O-β-D-glucuronopyranoside can be isolated from the aerial parts of C. rotundus L.. Luteolin 4'-O-β-D-glucuronopyranoside inhibits *α-amylase. Luteolin 4'-O-β-D-glucuronopyranoside shows antioxidant activity*. Luteolin 4'-O-β-D-glucuronopyranoside can be used in research on diabetes .

Cat. No.	Product Name	Type

HY-153102

G3-CNP	Biochemical Assay Reagents
G3-CNP is an α-amylase substrate. The absorbance of G3-CNP cleavage product 2-chloro-4-nitrophenol is measured at 405 nm, which can be used to detect enzyme activity .

HY-160113

Sodium phosphate buffer 0.02 M, pH 6.9

Biochemical Assay Reagents

Sodium phosphate buffer 0.02 M, pH 6.9 is a commonly used aqueous biological buffer that maintains a stable pH value. Sodium phosphate buffer 0.02 M, pH 6.9 is often used in enzyme activity assays, such as α-amylase assays. Sodium phosphate buffer 0.02 M, pH 6.9 is prepared by mixing disodium hydrogen phosphate (Na₂HPO₄) (HY-B2243) and sodium dihydrogen phosphate (NaH₂PO₄) (HY-Y0308) to a total concentration of 0.02 M .

HY-N1731

2′-Hydroxy-5′-methoxyacetophenone

Biochemical Assay Reagents

2'-Hydroxy-5'-methoxyacetophenone is an acetophenone derivative with acaricidal activities. 2'-Hydroxy-5'-methoxyacetophenone attenuates the inﬂammatory response via NF-κB signaling pathway. 2'-Hydroxy-5'-methoxyacetophenone exhibits significant inhibitory activity against α-amylase, collagenase and aldose reductase (AR) with IC₅₀s of 0.928, 3.264 and 20.046 μM, highlighting its potential in combating diabetes. 2'-Hydroxy-5'-methoxyacetophenone exhibits anti-ovarian cancer activity .

Cat. No.	Product Name	Target	Research Area

HY-P2055

A-57696	Endogenous Metabolite	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

α-amylase activity

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Natural
Products